PD-7 Osemitamab Plus Capecitabine and Oxaliplatin (CAPOX) As the First-Line Treatment of Advanced G/GEJ Cancer – Updated Efficacy Data Per Claudin 18.2 Expression Level from Study TranStar102/TST001-1002-cohort C

L. Shen,D. Liu,N. Li,W. Guo,T. Liu,H. Li,J. Li,F. Zhao,M. Sun,Y. Bai,Y. Deng,Z. Zhuang,Q. Fan,L. Han,S. Xia,X. Zhu,C. Qi,L. Xu,X. Qian,C. Germa

DOI: https://doi.org/10.1016/j.annonc.2023.04.034

IF: 51.769

2023-01-01

Annals of Oncology

Abstract:Claudin18.2 antibody plus chemotherapy is a clinically validated approach for patients with high CLDN18.2 expressing tumors, which has been proven by zolbetuximab. Osemitamab is a best-in-class differentiated antibody with optimized Fc glycosylation, having improved CLDN18.2 affinity and enhanced antibody-dependent cellular cytotoxicity, leads to anti-tumor activity in low to medium CLDN18.2 expressors gastric cancer cells. Pre-clinical studies also showed that osemitamab has stronger tumor regression effects than the IMAB362-analog at the same dose. The efficacy and safety of osemitamab plus CAPOX as first-line treatment with advanced G/GEJ cancer was explored in a dose escalation and expansion phase 1/2 study in China (Cohort C, NCT04495296). Positive claudin18.2 (membranous staining ≥1+ in ≥10% of tumor cells) as assessed centrally using the LDT assay was required in the expansion phase only. As of January 31, 2023, 64 patients were dosed with osemitamab in combination with CAPOX, 15 patients received osemitamab at doses ranging from 1 to 8 mg/kg Q3W in the dose escalation and 49 patients at 6 mg/kg in the dose expansion. The median follow up was 165 days. Patient characteristics were typical of 1st-line G/GEJ cancer, with high percentage of peritoneal disease (40.6%). Gastrointestinal reaction (nausea 65.4% and vomiting 48.1%) and hypoalbuminemia (69.2%) were the most common adverse events related to TST001 at dose of 6mg/kg in 52 patients (3 patients in dose escalation and 49 patients in dose expansion). Most of them were grade 1 or 2, only one patient experienced grade 3 nausea and vomiting. 42 of the 45 patients with measurable lesions had at least one post-treatment tumor assessment in dose expansion as of cut-off date. 28 achieved partial response with 23 confirmed, 13 achieved stable disease, overall response rate (ORR) was 66.7%, disease control rate was 97.6%, there was no notable difference in ORR per CLDN18.2 level. Progression free survival (PFS) and duration of response (DOR) were still immature but ORR, PFS, DOR etc will be updated and presented by CLDN18.2 level at the time of the congress. Osemitamab plus CAPOX as first-line treatment for patients with G/GEJ cancer demonstrated good safety and tolerability. Encouraging anti-tumor activities have been observed regardless of the CLDN18.2 expression levels above 10%, 1+ per central LDT assay.